Welcome to our dedicated page for Oculis Holding SEC filings (Ticker: OCS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Oculis Holding's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Oculis Holding's regulatory disclosures and financial reporting.
Oculis Holding AG reported a 2025 net loss of CHF 98.96m, compared with a CHF 85.78m loss in 2024, as it advanced late-stage ophthalmic drug development. Research and development expenses rose to CHF 57.1m, while general and administrative costs reached CHF 25.8m, driven mainly by clinical programs and share-based compensation.
Despite ongoing losses, Oculis strengthened its balance sheet. Cash and cash equivalents were CHF 81.33m and short-term financial assets were CHF 131.68m as of December 31, 2025, following underwritten offerings totaling CHF 178.9m in gross proceeds. Total equity increased to CHF 196.07m and total assets to CHF 235.96m, giving the company resources to fund its pipeline.
Separately, Oculis renewed its at-the-market equity program by entering into an amended and restated sales agreement with Leerink Partners tied to a new Form F-3 shelf registration. The ATM program permits offers and sales, at the company’s discretion, of ordinary shares up to an aggregate offering price of $100m through Leerink Partners as sales agent.
Oculis Holding, a late clinical-stage biopharmaceutical company focused on ophthalmic and neuro‑ophthalmic diseases, reports continued pre‑revenue investment in its pipeline, including OCS‑01 for diabetic macular edema, Licaminlimab for dry eye disease and Privosegtor for optic neuritis and related conditions.
For the year ended December 31, 2025, Oculis recorded a net loss of CHF 99.0 million, compared with CHF 85.8 million in 2024, bringing accumulated losses to CHF 384.5 million. The company held CHF 213.0 million in cash, cash equivalents and short‑term financial assets, which it believes will fund operations for at least the next twelve months. As of December 31, 2025, it had 57,984,438 ordinary shares, 2,104,906 warrants to purchase ordinary shares and 60 employees.
Oculis Holding reported a 2025 net loss of CHF 99.0 million (vs. CHF 85.8 million in 2024) as it stepped up investment in its late‑stage pipeline. Cash, cash equivalents and short‑term investments rose to CHF 213.0 million, or $268.7 million, helped by $210.0 million of equity financings in February and November 2025, giving a cash runway into 2029.
During 2025, the company obtained FDA Breakthrough Therapy designation for Privosegtor in optic neuritis and initiated the PIONEER‑1 registrational trial. Both Phase 3 DIAMOND trials of OCS‑01 in diabetic macular edema enrolled over 800 patients, with topline data expected in Q2 2026 and a possible NDA in Q4 2026 if results are positive. Oculis also launched the genotype‑based PREDICT‑1 registrational trial of Licaminlimab in dry eye disease, with topline results targeted for Q4 2026.
Oculis Holding AG filed a Form F-3 to register the resale of up to 494,259 ordinary shares by the selling securityholder. The shares are issuable upon exercise of a warrant originally issued on May 29, 2024 and amended on July 31, 2025. Oculis is not selling any securities under this prospectus and will not receive proceeds from resales; it would receive the warrant exercise price if exercised in cash.
The warrant is currently exercisable for 59,310 shares and may become exercisable for up to 494,259 shares based on draws under a three‑loan facility or a specified milestone. Exercise prices are $12.17 for 361,011 shares and $18.64 for 133,248 shares. If fully exercised for cash for the maximum shares, Oculis would receive $6,877,246.59. Shares outstanding were 52,374,811 as of September 30, 2025. The ordinary shares trade on Nasdaq and Nasdaq Iceland under the symbol OCS.
Oculis Holding AG filed a Form 6-K to furnish its unaudited financial results for the three and nine month periods ended September 30, 2025. The filing states that detailed figures and commentary are provided in attached unaudited condensed consolidated interim financial statements, a management discussion and analysis, and a press release. It also specifies that the Form 6-K, including the financial statements and MD&A but excluding the press release, is incorporated by reference into the company’s existing registration statements on Form S-8 and Form F-3, linking these updated results to previously registered securities.
Oculis Holding AG (OCS) is offering 4,691,358 ordinary shares at $20.25 per share and selling 740,740 shares in a concurrent registered direct offering. Underwriters have a 30‑day option to buy up to 703,703 additional shares.
The underwritten tranche reflects a $95.0 million gross raise with $5.7 million in underwriting commissions and $89.3 million proceeds before expenses. Across both transactions, Oculis estimates ~$102.5 million in net proceeds (or ~$115.5 million if the option is fully exercised). The company plans to fund and accelerate Privosegtor (OCS‑05) in acute optic neuritis (AON) and NAION, and for working capital and general corporate purposes.
Shares outstanding are expected to be 57,806,909 after the offering and concurrent sale (or 58,510,612 if the option is fully exercised), based on 52,374,811 shares outstanding as of September 30, 2025. Settlement is expected on a T+2 basis. The ordinary shares trade on Nasdaq and Nasdaq Iceland under “OCS.”
Oculis Holding AG is offering 740,740 ordinary shares at $20.25 per share in a registered direct sale to an investor. The company will receive $14,999,985 in gross proceeds, with estimated expenses of about $150,000.
The company is also conducting a concurrent underwritten offering of 4,691,358 shares, with an option for underwriters to buy up to 703,703 additional shares. Oculis estimates combined net proceeds of approximately $102.5 million (or $115.5 million if the option is fully exercised) to advance Privosegtor (OCS-05) in AON and NAION and for working capital and general corporate purposes.
Shares outstanding are expected to be 57,806,909 after this direct sale and the concurrent offering, based on 52,374,811 outstanding as of September 30, 2025. The company also terminated its prior $100 million ATM program with no shares sold.
Oculis Holding AG announced equity financings totaling 5,432,098 ordinary shares at $20.25 per share, split between an underwritten sale of 4,691,358 shares and a registered direct sale of 740,740 shares. The underwriters also have a 30‑day option to purchase up to 703,703 additional shares at the same price.
Gross proceeds are expected to be approximately $110.0 million, or $124.2 million if the option is exercised in full. The closings are expected on or about November 3, 2025, subject to customary closing conditions. The company states that net proceeds, together with existing cash, cash equivalents and short‑term investments, are expected to fund operations to late 2028. The offerings were made under an effective Form F‑3 shelf registration.
Oculis Holding AG suspended and terminated its at-the-market prospectus that permitted sales of up to $100 million of ordinary shares under its May 8, 2024 sales agreement with Leerink Partners. As of this report, no shares were sold under the ATM prospectus. The underlying sales agreement remains in effect, and any future sales would require a new prospectus, prospectus supplement or registration statement.